Business Context and Reporting Period
Company: Eli Lilly & Co.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: Eli Lilly is a global pharmaceutical company operating primarily in one significant segment: human pharmaceutical products. It also maintains an animal health business segment. The company discovers, develops, manufactures, and sells products in approximately 135 countries. Key therapeutic areas include neurosciences (e.g., Zyprexa, Cymbalta), endocrinology (e.g., Humalog, Byetta), oncology (e.g., Gemzar, Alimta, Erbitux), and cardiovascular (e.g., Cialis).
Key Financial Metrics
| Metric | 2008 | 2007 | Change |
|---|---|---|---|
| Net Sales | $20,378.0 million | $18,633.5 million | +9% |
| Gross Margin | 78.5% | 77.2% | +1.3 pts |
| Research & Development | $3,840.9 million | $3,486.7 million | +10% |
| Marketing, Selling, & Admin | $6,626.4 million | $6,095.1 million | +9% |
| Income (Loss) Before Taxes | ($1,307.6) million | $3,876.8 million | N/A |
| Net Income (Loss) | ($2,071.9) million | $2,953.0 million | N/A |
| Earnings Per Share (Diluted) | ($1.89) | $2.71 | ($4.60) |
| Cash Flow from Operations | $7,295.6 million | $5,154.5 million | +41.5% |
| Total Debt | $10,462.0 million | $5,012.0 million | +108.7% |
| Cash & Equivalents | $5,496.7 million | $3,220.5 million | +70.7% |
Material Changes Versus Prior Period
- Net Loss vs. Net Income: The company reported a net loss of $2.07 billion in 2008 compared to net income of $2.95 billion in 2007. This reversal was driven primarily by two significant non-recurring charges:
- ImClone Acquisition: A $4.69 billion charge for acquired in-process research and development (IPR&D) related to the acquisition of ImClone Systems Inc. in November 2008. This charge was not tax-deductible.
- Zyprexa Settlements: A $1.48 billion charge related to the resolution of federal and state government investigations regarding the marketing and promotional practices of Zyprexa.
- Revenue Growth: Despite the net loss, worldwide sales grew 9% to $20.38 billion. Growth was driven by volume increases in Cymbalta (+28%), Cialis (+26%), Alimta (+35%), and Humalog (+18%). Zyprexa sales declined slightly by 1% due to generic competition in certain markets.
- Debt Increase: Total debt increased by $5.45 billion to $10.46 billion, primarily due to the issuance of commercial paper to finance the ImClone acquisition.
- Acquisitions: In addition to ImClone, the company acquired SGX Pharmaceuticals ($64 million) and the worldwide rights to Posilac from Monsanto ($300 million upfront).
Guidance, Outlook, and Risks
2009 Guidance
- Earnings Per Share: Management expects diluted EPS in the range of $4.00 to $4.25 for the full year 2009.
- Sales Growth: Mid-single digit sales growth is expected, driven by Cymbalta, Alimta, Cialis, Humalog, and the anticipated launch of prasugrel (Efient). This is expected to be partially offset by weaker foreign currencies, pricing pressures, and generic competition for Gemzar.
- Expenses: Marketing, selling, and administrative expenses are expected to show flat to low-single digit growth. R&D expenses are projected to grow in the low-double digits.
- Capital Expenditures: Expected to be approximately $1.1 billion.
Key Risks and Contingencies
- Patent Litigation: The company faces significant patent challenges from generic manufacturers for key products including Cymbalta, Gemzar, Alimta, Evista, and Strattera. An unfavorable outcome could materially impact future results.
- Zyprexa Litigation: While government investigations were settled, product liability litigation continues. Approximately 120 claims remain in the U.S., and class actions are pending in Canada. The company is largely self-insured for future product liability losses.
- Regulatory and Pricing Pressures: Increasing government cost-containment measures, price controls, and reimbursement restrictions in both the U.S. and international markets pose a risk to profitability.
- Intellectual Property Expirations: Several major products, including Zyprexa (2011), Humalog (2013), and Cymbalta (2013), face patent expirations in the coming years, which could lead to generic competition and revenue declines.
Investor Verification Checklist
- ImClone Integration: Verify the progress of integrating ImClone's oncology pipeline and the commercial performance of Erbitux.
- Zyprexa Patent Status: Monitor the outcome of ongoing patent litigation in the U.S. and key international markets (e.g., Canada, Germany) to assess the timeline for generic entry.
- Product Liability Reserves: Review the adequacy of reserves for remaining Zyprexa product liability claims and the potential for future self-insured losses.
- Generic Competition: Track the launch dates and market share erosion for products facing patent expirations, specifically Gemzar (2010) and Zyprexa (2011).
- Debt Servicing: Assess the company's ability to service the increased debt load ($10.46 billion) while maintaining dividend payments and funding R&D.
- 2009 EPS Target: Evaluate the achievability of the $4.00-$4.25 EPS guidance given the exclusion of the 2008 non-recurring charges and the impact of foreign exchange rates.